AMLO Biosciences is developing innovative diagnostic tests for cancer detection using breakthroughs in biomarkers. Their products aim to reduce healthcare costs for low-risk cancers and boost patient survival. AMLO’s tests can identify truly high-risk patients needing vigilant monitoring, avoiding intensive screening for those with favourable outlooks. This both curbs healthcare spending on low-yield surveillance and spares patients needless anxiety. Their quest to alleviate patient distress and burden on healthcare systems mirrors our investment philosophy.